Results 81 to 90 of about 36,016 (212)

An Evaluation of Foreign Clinical Data in the Approval Reviews of Antimicrobial Medicines in Japan: Considering Ethnic and Regional Differences in Data Extrapolations in Accordance With Regulatory Circumstances

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT The approval requirements in new regions that do not require domestic clinical data and the clinical data evaluation of multi‐regional clinical trials (MRCTs) and foreign clinical trials (FCTs) in the Japanese approval review processes for antimicrobial medicines were explored.
Rumiko Shimazawa, Masayuki Ikeda
wiley   +1 more source

Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials

BMC Infectious Diseases, 2011
Background Interferon alpha (IFNα) therapy has been widely used in the treatment of chronic hepatitis B (CHB) for decades. Nucleos(t)ide analogues are also increasingly used to treat CHB recently.
Zhang Yu-guo, Ren Wei-guang, Kong Ling-bo, Wang Mao-rong, Li Wen-cong, Nan Yue-min   +5 more
doaj   +1 more source

Toward a Functional Cure for Chronic Hepatitis B: Current Landscape and Future Directions in Japan

Hepatology Research, Volume 56, Issue 6, Page 903-913, June 2026.
Hepatitis B is a viral liver infection that can become chronic, increasing the risk of developing liver cancer and liver failure. Because current treatments rarely cure these problems, researchers are now focusing on a functional cure in which the virus becomes undetectable in blood and stays that way, even after the treatment ends.
Yutaka Handa, Ethan Yichen Lee, Yasuhito Tanaka   +2 more
wiley   +1 more source

A one-year trial of lamivudine for chronic hepatitis B [PDF]

, 1998
Background and Methods: In preliminary trials, lamivudine, an oral nucleoside analogue, has shown promise for the treatment of chronic hepatitis B. We conducted a one-year double-blind trial of lamivudine in 358 Chinese patients with chronic hepatitis B.
Rong-Nan Chien, Barber, J, Stephenson, SL, Ng, KY, Leung, NWY, Gray, DF, Dent, JC, Dar-In Tai, Guan, R, Lai, CL, Nancy W.Y. Leung, Ting-Tsung Chang, Julie C. Dent, Richard Guan, Chien, RN, Judy Barber, Pui-Chee Wu, Tai, DI, Ching-Lung Lai, D. Fraser Gray, Chang, TT, Keng-Yeen Ng, Sally L. Stephenson, Wu, PC   +23 more
core   +1 more source

Formulation and evaluation of Lamivudine transferosomal gel

, 2022
Aim and objective: The aim of the study was to formulate and evaluate Transferosomal gel of lamivudine. Method:Lamivudine transferosomes was prepared using thin film hydration method taking span 80, Polyoxyethylene lauryl ether in different  ...
Yameen, Syeda Hassan, Shahidulla, S.M.
core   +1 more source

This Is Not a Myeloproliferative Neoplasm…

Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
Stephanie Juané Kennedy
wiley   +1 more source

Treatment durability, satisfaction and quality of life in virologically suppressed HIV‐1 people switching to doravirine: Results from the French study DoraVIH

HIV Medicine, Volume 27, Issue 6, Page 886-895, June 2026.
Abstract Objectives In Europe, most people with HIV‐1(PWH) achieve virologic suppression with effective and well‐tolerated antiretroviral therapies (ART). In this context, patient‐reported outcomes (PRO) are increasingly important for evaluating ART benefits.
Spire Bruno, Robineau Olivier, Pourcher Valérie, Loubet Paul, Palacios Christia, Jacomet Christine, Benachir Haydar, Mariot Philippe, Parienti Jean‐Jacques, Slama Laurence   +9 more
wiley   +1 more source

Prolonged Persistence of Lamivudine-resistant Mutant and Emergence of New Lamivudine-resistant Mutants Two Years After Lamivudine Withdrawal in HBsAg-positive Chronic Hepatitis Patient: A Case Report

, 2008
Lamivudine can select resistant hepatitis B virus (HBV) tyrosine-methionine-aspartate-aspartate aminoacid motif (YMDD) mutants, which usually disappear in few months after lamivudine withdrawal.
D'ONOFRIO M, TOSONE, GRAZIA, ORLANDO, RAFFAELE, VEROPALUMBO E, PORTELLA, GIUSEPPE, PIAZZA, MARCELLO   +5 more
core   +1 more source

Detection of the YMDD Motif Mutations Rate in Chronic Hepatitis B Patients Treated with Lamivudine

Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Qum, 2011
Background and Objectives: Lamivudine is the first nucleoside analogue licensed for the treatment of chronic hepatitis B patients which is effective in suppressing virus replication and results in reduced disease activity.
R Rafiei Tabatabaei, R Ehsani, A Pouryasin, A Soudbakhsh, H Sharafi   +4 more
doaj  

Cost-effectiveness of telbivudine versus lamivudine for chronic hepatitis B

Brazilian Journal of Infectious Diseases
BACKGROUND AND AIM: Chronic hepatitis B is a highly prevalent disease worldwide, leading to serious consequences if not properly treated. Six treatment options for chronic hepatitis B are currently provided by the Brazilian public health system ...
Astrid Wiens, Rafael Venson, Cassyano Januário Correr, Roberto Pontarolo   +3 more
doaj   +1 more source